Insulin degludec compared with insulin glargine in insulin‐naïve patients with type 2 diabetes: <scp>A</scp> 26‐week, randomized, controlled, <scp>P</scp>an‐<scp>A</scp>sian, treat‐to‐target trial

Abstract

Initiating insulin therapy with IDeg in Asian patients with type 2 diabetes, inadequately controlled with OADs, provides similar improvements in long-term glycemic control to IGlar, but at a significantly lower rate of overall confirmed hypoglycemia once stable glycemic control and insulin dosing are achieved. This trial was registered with www.clinicaltrials.gov (no. NCT01059799).